Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (34)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Lowndes, S.
Right arrow Articles by Lister, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lowndes, S.
Right arrow Articles by Lister, A.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Annals of Oncology 13:1948-1950, 2002
© 2002 European Society for Medical Oncology

Clinical Investigations

Stevens–Johnson syndrome after treatment with rituximab

S. Lowndes1,+, A. Darby1, G. Mead1 and A. Lister2

1 Cancer Research UK Department of Medical Oncology, Royal South Hants Hospital, Southampton; 2 Cancer Research UK Department of Medical Oncology, St Bartholomew’s Hospital, London, UK

Received 26 August 2002; accepted 16 September 2002

Abstract

Rituximab is a chimeric mouse/human anti-CD20 antibody licensed for the treatment of low-grade non-Hodgkin’s lymphoma and has recently also been shown to have a role in the treatment of diffuse large B-cell lymphoma. We report a case of Stevens–Johnson syndrome after treatment with rituximab, which occurred in a 36-year-old man with relapsed follicular lymphoma. The patient developed mucositis and fevers after the first two injections, followed by a florid maculopapular rash with severe orogenital ulceration after the third infusion. Over several weeks his symptoms progressed with severe cutaneous, orogenital and conjunctival ulceration, leading to visual problems and malnutrition. No improvement occurred with steroids and immunosuppressant therapy. A review of the literature reveals this to be the first reported case of Stevens–Johnson syndrome associated with rituximab therapy.

Key words: Stevens–Johnson syndrome, rituximab, side effects, follicular lymphoma


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 JCOHome page
C. P. Castaneda, N. A. Brandenburg, R. Bwire, G. H. Burton, and J. B. Zeldis
Erythema Multiforme/Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis in Lenalidomide-Treated Patients
J. Clin. Oncol., January 1, 2009; 27(1): 156 - 157.
[Full Text] [PDF]

Home page
 Ann OncolHome page
D Errante, D Bernardi, A Bianco, S De Nardi, and L Salvagno
Rituximab-related urticarial reaction in a patient treated for primary cutaneous B-cell lymphoma
Ann. Onc., November 1, 2006; 17(11): 1720 - 1721.
[Full Text] [PDF]

Home page
 Arch DermatolHome page
S. H. Jaber, E. W. Cowen, L. R. Haworth, S. L. Booher, D. M. Berman, S. A. Rosenberg, and S. T. Hwang
Skin Reactions in a Subset of Patients With Stage IV Melanoma Treated With Anti-Cytotoxic T-Lymphocyte Antigen 4 Monoclonal Antibody as a Single Agent.
Arch Dermatol, February 1, 2006; 142(2): 166 - 172.
[Abstract] [Full Text] [PDF]

Home page
 LupusHome page
S A Chambers and D Isenberg
Anti-B cell therapy (Rituximab) in the treatment of autoimmune diseases
Lupus, March 1, 2005; 14(3): 210 - 214.
[Abstract] [PDF]

Home page
 Ann OncolHome page
B. Hellerstedt and A. Ahmed
Delayed-type hypersensitivity reaction or serum sickness after rituximab treatment
Ann. Onc., December 1, 2003; 14(12): 1792 - 1792.
[Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.